

~~Under the Paperwork Reduction Act, a fee is required for form 1449A/PTO.~~

PTO/SB/08A (06-03)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>										
Sheet	1	of	'2	Attorney Docket Number										
				UBC.P-030										
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/846,436</td> </tr> <tr> <td>Filing Date</td> <td>8/21/2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Gleave et al.</td> </tr> <tr> <td>Art Unit</td> <td>1645</td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> </table>					Application Number	10/846,436	Filing Date	8/21/2003	First Named Inventor	Gleave et al.	Art Unit	1645	Examiner Name	
Application Number	10/846,436													
Filing Date	8/21/2003													
First Named Inventor	Gleave et al.													
Art Unit	1645													
Examiner Name														

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

### Sheets

1

of

2

Application Number	10/646,436
Filing Date	8/21/2003
First Named Inventor	Gleave et al.
Unit	1645
Examiner Name	
Priority Document Number	U.S.C. 3.200

## U.S. PATENT DOCUMENTS

U.S. PATENT APPLICATION PUBLICATIONS


CITED PATENT APPLICATION/CITED DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (If known)	MM-DD-YYYY		
		US-2002/0086356 A1	07/04/2002	Tuschl et al.	
		US-2003/0158130 A1	08/21/2003	Gleave et al.	
		US-			

## FOREIGN PATENT DOCUMENTS

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of US PTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including the gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (06-03)

Approved for use through 06/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	2	Attorney Docket Number	UBC.P-030
-------	---	----	---	------------------------	-----------

### NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KC		CARTHEW, Gene silencing by double-stranded RNA, Current Opinion in Cell Biology, 2001, Page(s) 244-248, Volume 13	
KC		DEMATTOS ET AL., Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease, PNAS, 2002, Page(s) 10843-10848, Volume 99, Number 16	
KC		ELBASHIR ET AL., Duplexes of 21 -nucleotide RNAs mediate RNA interference in cultured mammalian cells, Nature, 2001, Page(s) 494-498, Volume 411	
KC		FIRE ET AL., Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> , Nature, 1998, Page(s) 806-811, Volume 391	
KC		YANG ET AL., Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death, PNAS, 2000, Page(s) 5907-5912, Volume 97, Number 11	

Examiner Signature	Karen Chay	Date Considered	7.12.05
--------------------	------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
to a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitution for form 1449APT

 <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		<small>FOR A COLLECTION OF INFORMATION WHICH IS DISPLAYED A VALID OEM CONTRACT</small> <b>Complete if Known</b>											
Sheet	1	of	2										
		Attorney Docket Number											
		UBC.P-030											
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;">Application Number</td> <td>10/646,436</td> </tr> <tr> <td>Filing Date</td> <td>8/21/2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Gleave et al.</td> </tr> <tr> <td>Art Unit</td> <td>1645</td> </tr> <tr> <td>Examiner Name</td> <td></td> </tr> </table>				Application Number	10/646,436	Filing Date	8/21/2003	First Named Inventor	Gleave et al.	Art Unit	1645	Examiner Name	
Application Number	10/646,436												
Filing Date	8/21/2003												
First Named Inventor	Gleave et al.												
Art Unit	1645												
Examiner Name													

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

She

1

8

2

Docket Number: MRC-B-666

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature	Kimberly Chan	Date Considered	7-12-05
--------------------	---------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of US PTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	10/648,436
Sheet	2	of	2	Filing Date	8/21/2003
				First Named Inventor	Gleave et al.
				Art Unit	1645
				Examiner Name	
				Attorney Docket Number	UBC P-030


NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
KC		DAVIES ET AL., Mutations of the BRAF gene in human cancer, Nature, 2002, Page(s) 949-954, Volume 417				
KC		GEWIRTZ, A Critical Evaluation of the Mechanisms of Action Proposed for the Antitumor Effects of the Anthracycline Antibiotics Adriamycin and Daunorubicin , Biochemical Pharmacology, 1999, Page(s) 727-741, Volume 57				
KC		HARBORTH ET AL., Identification of essential genes in cultured mammalian cells using small interfering RNAs, Journal of Cell Science, 2001, Page(s) 4557-4565, Volume 114				
KC		LESKOV ET AL., Synthesis and Functional Analyses of Nuclear Clusterin, a Cell Death Protein, The Journal of Biological Chemistry, 2003, Page(s) 11590-11600, Volume 278, Number 13				
KC		MCGILL ET AL., Bcl2 Regulation by the Melanocyte Master Regulator Mitf Modulates Lineage Survival and Melanoma Cell Viability, Cell, 2002, Page(s) 707-718, Volume 109				
KC		MULLER ET AL., Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion, Cancer Chemother Pharmacol, 1993, Page(s) 379-384, Volume 32				
KC		ROHLFF ET AL., Prostate Cancer Cell Growth Inhibition by Tamoxifen Is Associated With Inhibition of Protein Kinase C and Induction of p21 <sup>Waf1/Cip1</sup> , The Prostate, 1998, Page(s) 51-59, Volume 37				

Examiner Signature	<i>Liberty Cheng</i>	Date Considered	7.12.05
--------------------	----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
to a collection of information unless it displays a valid OMB control number.

Under the Privacy Protection Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**Substitute for form 1449A/PTO**

**Complete if Known**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

<p>Substitute for form 1449A/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>				<p><b>Complete if Known</b></p>	
Sheet	1	of	4	Application Number	10/646,436
				Filing Date	8/21/2003
				First Named Inventor	Gleave et al.
				Art Unit	1645
				Examiner Name	
				Attorney Docket Number	UBC.P-030

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner  
Signature

Aberl Chan

Date  
Considered

71205

**\*EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **<sup>1</sup>Applicant's unique citation designation number (optional).** **<sup>2</sup>See Kinds Codes of US PTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.** **<sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).** **<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.** **<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.** **<sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.**

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete If Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>		<i>Application Number</i>	10/646,436		
		<i>Filing Date</i>	8/21/2003		
		<i>First Named Inventor</i>	Gleave et al.		
		<i>Art Unit</i>	1645		
		<i>Examiner Name</i>			
Sheet	2	of	4	Attorney Docket Number	UBC.P-030

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
KC		AGAMI , RNAi and related mechanisms and their potential use for therapy. Current Opinion in Chemical Biology, 2002, Page(s) 829-834, Volume 6, Publisher: Current Biology Ltd, London, GB XP00295888			
KC		BRUMMELKAMP ET AL., A system for stable expression of short interfering RNAs in mammalian cells, Science, 2002, Page(s) 550-553, Volume 296, Number 5567, Publisher: American Association for the Advancement of Science, US, XP002234902			
KC		CALERO ET AL., Apolipoprotein J (Clusterin) and Alzheimer's Disease, Microscopy Research and Technique, 2000, Page(s) 305-315, Volume 50, Number 4, XP009021345			
KC		CHOI-MIURA ET AL., Relationship Between Multifunctional Protein "Clusterin" and Alzheimer Disease, Neurobiology of Aging, 1996, Page(s) 717-722, Volume 17, Number 5, XP001146408			
KC		DEMIR ET AL., Use of RNA Interference (RNAi) to Disrupt C-Kit Gene Expression in Malignant Human Hematopoietic and Neuroepithelial Cells, Blood, 2000, Page(s) 378B, Volume 96, Number 11, Part 2, Publisher: W. B. Saunders Company, Orlando, FL, US, Abstract #5389, XP009004894			
KC		GLEAVE ET AL., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2, to Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer, Urology, 2001, Page(s) 39-49, Volume 58, XP002262320			
KC		GLEAVE ET AL., Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer, Investigational New Drugs, 2002, Page(s) 145-158, Volume 20, Number 2, XP 009021411			
KC		HOJOH , RNA interference (RNAi) induction with various types of synthetic oligonucleotide duplexes in cultured human cells, FEBS Letters, 2002, Page(s) 195-199, Volume 521, Number 1-3, Publisher: Elsevier Science Publishers, Amsterdam, NL XP004362164			
KC		JONES ET AL., Molecules in focus: Clusterin, The International Journal of Biochemistry & Cell Biology, 2002, Page(s) 427-431, Volume 34, XP002262319			
KC		KOCH-BRANDT ET AL., Clusterin: A Role in Cell Survival in the Face of Apoptosis?, Progress in Molecular and Subcellular Biology, 1996, Page(s) 130-149, Volume 16, XP009021385			
KC		MIYAKE ET AL., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both in Vitro and in Vivo, Clinical Cancer Research, 2000, Page(s) 1655-1663, Volume 6, Number 5, Publisher: The American Association for Cancer Research, US, XP000960694			

Examiner Signature	<i>Kimberly Chong</i>	Date Considered	7-12-05
--------------------	-----------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	10/646,436
		Filing Date	8/21/2003
		First Named Inventor	Gleave et al.
		Art Unit	1645
		Examiner Name	
Sheet 1 of 3		Attorney Docket Number	UBC.P-030

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
KC		MIYAKE ET AL., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity., International Journal of Urology, 2001, Page(s) 337-349, Volume 8, Number 7, XP002262321		
KC		PADDISON ET AL., Stable suppression of gene expression by RNAi in mammalian cells, Proceedings of the National Academy of Sciences of USA, 2002, Page(s) 1443-1448, Volume 99, Number 3, Publisher: National Academy of Science, XP002958887		
KC		ROSENBERG ET AL., Clusterin: Physiologic and Pathophysiologic Considerations, Int. J. Biochem. Cell Biol., 1995, Page(s) 633-645, Volume 27, Number 7, XP001002844		
KC		SENSIBAR ET AL., Prevention of Cell Death Induced by Tumor Necrosis Factor $\alpha$ in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 (Clusterin), Cancer Research, 1995, Page(s) 2431-2437, Volume 55, Publisher: American Association for Cancer Research, Baltimore, MD, US, XP002930082		
KC		SHARP, RNAi and double-strand RNA, Genes and Development, 1999, Page(s) 139-141, Volume 13, Number 2, Publisher: Cold Spring Harbor Laboratory Press, New York, US, XP002171268		
KC		STROCCHI ET AL., Neuronal loss up-regulates clusterin mRNA in living neurons and glial cells in the rat brain, NeuroReport, 1999, Page(s) 1789-1792, Volume 10, Number 8, Publisher: Rapid Communications of Oxford, Oxford, GB, XP009017327		
KC		SUI ET AL., A DNA vector-based RNAi technology to suppress gene expression in mammalian cells, Proceedings of the National Academy of Sciences of USA, 2002, Page(s) 5515-5520, Volume 99, Number 8, Publisher: National Academy of Science, Washington, US, XP002964701		
KC		TUSCHL ET AL., Targeted mRNA degradation by double-stranded RNA in vitro, Genes and Development, 1999, Page(s) 3191-3197, Volume 13, Number 24, Publisher: Cold Spring Harbor Laboratory Press, New York, US, XP002183118		
KC		UEDA, RNAi: A new technology in the post-genomic sequencing era, Journal of Neurogenetics, 2001, Page(s) 193-204, Volume 15, Number 3/4, Publisher: Elsevier, Amsterdam, NL, XP001147227		
KC		WILSON ET AL., Clusterin is a secreted mammalian chaperone, Trends in Biochemical Sciences, 2000, Page(s) 95-98, Volume 25, No. 3, Publisher: Elsevier Publication, Cambridge, EN, XP004202536		
KC		WONG ET AL., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration, European Journal of Biochemistry, 1994, Page(s) 917-925, Volume 227, Number 3, XP 001146404		

Examiner Signature	<i>Wendy Chon</i>	Date Considered	7.12.05
--------------------	-------------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<p>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.</p> <p><b>Substitute for form 1449B/PTO</b></p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>			
<p><b>Complete If Known</b></p>		<b>Application Number</b>	10/646,436
		<b>Filing Date</b>	B/21/2003
		<b>First Named Inventor</b>	Gleave et al.
		<b>Art Unit</b>	1645
		<b>Examiner Name</b>	
<b>Sheet</b>	4	<b>of</b>	4
		<b>Attorney Docket Number</b>	UBC P-030

Examiner Signature	Kubertly Chone	Date Considered	7/11/05
-----------------------	----------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**1** Applicant's unique citation designation number (optional). **2** Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



ATTORNEY DOCKET NO. UBC.P-030

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT

Application No: 10/646,436  
Filing Date: August 21, 2003  
First Named Inventor: Gleave, et al.  
Confirmation No.: 9171  
Group Art Unit: 1645  
Examiner Name:  
Attorney Docket No.: UBC.P-030

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Office	Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
KC	WO	00/69454	Chakrabarty, et al.	November 23, 2000

Examiner's Initials	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
KC	Chacko, et al.: "Double-Stranded Ribonucleic Acid Decreases C6 Rat Glioma Cell Numbers: Effects on Insulin-Like Growth Factor I Gene Expression and Action"; Endocrinology, Vol. 141, No. 10: 3546-3555; October 2000.
KC	Miyake, et al.: "Castration-Induced Up-Regulation of Insulin-Like Growth Factor Binding Protein-5 Potentiates Insulin-Like Growth Factor-I Activity and Accelerates Progression to Androgen Independence in Prostate Cancer Models"; Cancer Research Vol. 60, No. 11: 3058-3064, June 1, 2000.
KC	Pavelić, et al.: "Insulin-Like Growth Factor Family and Combined Antisense Approach in Therapy of Lung Carcinoma"; Molecular Medicine Vol. 8, No. 3: 149-157, March 2002.

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner: Kimberly Chong Date Considered: 7-11-05